So, what’s left? XwinSys, which was supposed to produce a few million dollars in sales by the end of 2017, has produced nothing and seemingly has been scaled back to “we will continue our sales efforts”.
Xenemetrix is dead in the water with minimal sales and ridiculous overhead costs.
Croptimal is a R&D cost bottomless barrel with no prospects of meaningful income in the foreseeable future.
So, this leaves SICPA royalties. In 2 years they have scored one rather inconsequential contract. Even if they score something more substantial before the royalty deal expires, what are the odds of shareholders benefitting?
EUO has history of “redirecting” funds. Increased R&D and we all know where that goes, huge salaries and bonuses. They sold their main business below cost and yet collect bonuses for doing so … ??? The equivalent of one year salaries to already overblown salaries for admitting that they couldn’t make a go of GFI.
What a gig if you can get it !!!